Omalizumab Improves Angioedema-Related Quality of Life Impariment in Patients with Chronic Idiopathic/Chronic Spontaneous Urticaria: Results from the X-Act Study

Main Article Content

Karsten Weller
Petra Staubach
Martin Metz
Nadine Chapman-Rothe
Christian Sieder
Matthias Brautigam
Marcus Maurer


urticaria, omalizumab, chronic urticaria, biologic therapy


Abstract not available.


Disclosures: Study supported by Novartis.


Copyright 2018 SKIN